These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 30479769)

  • 21. Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia.
    Benton CB; Boddu PC; DiNardo CD; Bose P; Wang F; Assi R; Pemmaraju N; Kc D; Pierce S; Patel K; Konopleva M; Ravandi F; Garcia-Manero G; Kadia TM; Cortes J; Kantarjian HM; Andreeff M; Verstovsek S
    Cancer; 2019 Jun; 125(11):1855-1866. PubMed ID: 30811597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series.
    Bayrak AG; Daglar Aday A; Yavuz AS; Nalcaci M; Ozbalak MM; Cefle K; Ozturk S; Palanduz S
    Leuk Res; 2021 Dec; 111():106725. PubMed ID: 34634595
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Outgrowth of a CSF3R-mutant clone drives a second myeloproliferative neoplasm in a chronic myeloid leukemia patient: a case report.
    Carratt SA; Brewer D; Maxson JE; Druker BJ; Braun TP
    Biomark Res; 2021 Jan; 9(1):8. PubMed ID: 33516272
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimal Response in a Patient With CML Expressing
    Manzella L; Tirrò E; Vitale SR; Puma A; Consoli ML; Tambè L; Pennisi MS; DI Gregorio S; Romano C; Tomarchio C; DI Raimondo F; Stagno F
    In Vivo; 2020; 34(3):1481-1486. PubMed ID: 32354950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is Allogeneic Transplantation an Option in Patients Affected by Concurrent Myelofibrosis and Chronic Myeloid Leukemia (CML)?
    Sora F; Chiusolo P; Autore F; Giammarco S; Laurenti L; Innocenti I; Metafuni E; Galli E; Bacigalupo A; Sica S
    Mediterr J Hematol Infect Dis; 2021; 13(1):e2021062. PubMed ID: 34804436
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emergence of
    Lorenzo M; Grille S; Stevenazzi M
    J Hematol; 2020 Apr; 9(1-2):23-29. PubMed ID: 32362982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice.
    Walz C; Ahmed W; Lazarides K; Betancur M; Patel N; Hennighausen L; Zaleskas VM; Van Etten RA
    Blood; 2012 Apr; 119(15):3550-60. PubMed ID: 22234689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Leukemia cell lines: in vitro models for the study of Philadelphia chromosome-positive leukemia.
    Drexler HG; MacLeod RA; Uphoff CC
    Leuk Res; 1999 Mar; 23(3):207-15. PubMed ID: 10071072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A rare atypical chronic myeloid leukemia BCR-ABL1 negative with concomitant
    Gao T; Yu C; Xia S; Liang T; Gu X; Liu Z
    Ther Adv Hematol; 2020; 11():2040620720927105. PubMed ID: 32782768
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.
    Theocharides A; Boissinot M; Girodon F; Garand R; Teo SS; Lippert E; Talmant P; Tichelli A; Hermouet S; Skoda RC
    Blood; 2007 Jul; 110(1):375-9. PubMed ID: 17363731
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
    Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BCR-ABL1(+) acute myeloid leukemia: clonal selection of a BCR-ABL1(-) subclone as a cause of refractory disease with nilotinib treatment.
    Neuendorff NR; Schwarz M; Hemmati P; Türkmen S; Bommer C; Burmeister T; Dörken B; le Coutre P; Arnold R; Westermann J
    Acta Haematol; 2015; 133(2):237-41. PubMed ID: 25401297
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
    Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
    N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BCR-ABL1 positive AML or CML in blast crisis? A pediatric case report with inv(3) and t(9;22) in the initial clone.
    Behrens YL; Schienke A; Davenport C; Lentes J; Tauscher M; Steinemann D; Rasche M; Knirsch S; Joachim S; Reinhardt D; Schlegelberger B; Göhring G
    Cancer Genet; 2021 Jun; 254-255():70-74. PubMed ID: 33647814
    [TBL] [Abstract][Full Text] [Related]  

  • 35. JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.
    Aynardi J; Manur R; Hess PR; Chekol S; Morrissette JJD; Babushok D; Hexner E; Rogers HJ; Hsi ED; Margolskee E; Orazi A; Hasserjian R; Bagg A
    Br J Haematol; 2018 Jul; 182(1):78-85. PubMed ID: 29767839
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
    Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
    Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Myeloproliferative Neoplasm or Reactive Process? A Rare Case of Acute Myeloid Leukemia and Transient Posttreatment Megakaryocytic Hyperplasia with JAK-2 Mutation.
    Wang S; Yan J; Zhou G; Heintzelman R; Hou JS
    Case Rep Hematol; 2016; 2016():6054017. PubMed ID: 27752371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
    Bellucci S; Michiels JJ
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transformation of an Unclassified Myeloproliferative Neoplasm with a Rare BCR-JAK2 Fusion Transcript Resulting from the Translocation (9;22)(p24;q11).
    Chamseddine AN; Etancelin P; Penther D; Parmentier F; Kuadjovi C; Camus V; Contentin N; Lenain P; Bastard C; Tilly H; Jardin F
    Case Rep Hematol; 2015; 2015():252537. PubMed ID: 25789185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.